Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness Clinical selection for Dimenhydrinate should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
Directions do not take more than directed to prevent motion sickness, the first dose should be taken 1/2 to 1 hour before starting activity to prevent or treat motion sickness, see below: adults and children 12 years and over take 1 to 2 tablets every 4-6 hours do not take more than 8 tablets in 24 hours, or as directed by a doctor children 6 to under 12 years give 1/2 to 1 tablet every 6-8 hours do not give more than 3 tablets in 24 hours, or as directed by a doctor children 2 to under 6 years give 1/2 tablet every 6-8 hours do not give more than 1 1/2 tablets in 24 hours, or as directed by a doctor
Drowsiness; psychomotor impairment; anti-muscarinic effects [e.g. urinary retention; dry mouth; GI disturbances; blurred vision]; allergic reactions; epileptic form seizure in patients with cerebral cortex focal lesion; muscle weakness; tachycardia; tight chest; paradoxical CNS stimulation - mostly in children.
Store as labelled. Keep out of reach of children.